Apply User Fees To Postmarket Data Collection In MDUFA IV, Pew Argues
This article was originally published in The Gray Sheet
Executive Summary
In the next round of MDUFA talks, FDA should target some industry user fees at gathering postmarket data, to support FDA’s growing emphasis on relying on postmarket data to resolve premarket uncertainties, Pew says in Aug. 12 comments.
You may also be interested in...
Industry Challenges FDA's User Fee Markup
During the first round of user fee negotiations, industry questioned FDA's estimated cost of $750 million needed to continue the device user fee program between 2018 and 2022. Lobby groups for the device industry continue to emphasize user fees should supplement congressional appropriations to pay for FDA's review of devices.
Calls For More FDA Training In Lead Up To User-Fee Negotiations
Device firms will be pushing for more reviewer consistency and to avoid a major increase in fees during upcoming negotiations with FDA to reauthorize the Medical Device User Fee Act. The MDUFA IV reauthorization process starts as Congress is already considering major regulatory reforms and will finish under a new administration in the White House.
'Cures' Bill Passes, As More Budget, Safety Debates Wait In The Wings
The 21st Century Cures bill passed on a 344-77 vote, attracting significant bipartisan support in the House. It includes multiple provisions supported by the device industry, including a priority review pathway for breakthrough devices. Attention now moves to the Senate, which is working on its own bill that could face budget barriers and calls for more safety protections.